Tesamorelin

Buy Tesamorelin: Research-Grade GHRH Analogue for Metabolic Studies

Searching for a reliable source to buy Tesamorelin? Sino Research Peptide Manufacturer supplies high-purity Tesamorelin peptide, formulated specifically for laboratory and research use. Below, you’ll find a full research overview of this GHRH analogue, along with everything you need to know before you buy Tesamorelin online.

What Is Tesamorelin Peptide?

Tesamorelin is a synthetic polypeptide made up of 44 amino acids, structurally similar to growth hormone-releasing hormone (GHRH). Researchers modified the N-terminus of the compound compared to natural GHRH, and this change may lead to improved stability.

Scientists have studied Tesamorelin’s mechanism of action as similar to GHRH receptors located at the anterior pituitary gland, potentially increasing the production and secretion of growth hormone. In turn, growth hormone may act on several cell types, including hepatocytes, stimulating the systemic synthesis of insulin-like growth factor-1 (IGF-1). Growth hormone may also stimulate IGF-1 production locally, inside various tissues.

How Does Tesamorelin Work?

GH and IGF-1 Stimulation

Researchers consider IGF-1 the main anabolic mediator of growth hormone, potentially stimulating growth and inhibiting programmed cell death. Growth hormone itself is thought to be lipolytic, inducing fat breakdown at specific adipose depots, such as abdominal and visceral fat.

Buy Tesamorelin appears to stimulate the release of growth hormone, and consequently IGF-1, by interacting with GHRH receptors in the anterior pituitary gland. When this interaction occurs, researchers hypothesize that it may alter the receptor’s structure, potentially initiating communication pathways within the cell.

The cAMP-PKA Signalling Pathway

Tesamorelin is also theorized to enhance the production of cyclic adenosine monophosphate (cAMP) in certain cells. This process may occur through stimulation of adenylate cyclase, an enzyme that converts ATP into cAMP. Increased cAMP levels may activate protein kinase A (PKA), an enzyme considered critical for transmitting cellular signals. Activated PKA may then phosphorylate target proteins, triggering a cascade of cellular responses that promote GH secretion from somatotroph cells in the pituitary gland.

Research indicates that Tesamorelin may lead to an estimated 69% increase in overall growth hormone levels, measured by area under the curve (AUC), along with a reported 55% increase in mean GH pulse area. Interestingly, it doesn’t appear to influence the frequency or peak levels of GH pulses. IGF-1 levels, meanwhile, reportedly surged by 122%.

Structural Modifications for Stability

Researchers altered both the N-terminus and C-terminus of the GHRH molecule to create Tesamorelin, potentially lending stability and increasing resistance to enzyme deactivation compared to natural GHRH. Specifically, the C-terminus is modified with a trans-3-hexenoic acid group — an omega-amino acid modification believed to reinforce the peptide’s defense against enzymatic breakdown. Meanwhile, the N-terminus carries an acetyl group (CH₃CO-), which may enhance both stability and biological activity.

As a result of these modifications, researchers designate Tesamorelin chemically as N-(trans-3-hexenoyl)-[Tyr1]hGRF(1–44)NH2 acetate.

Chemical Makeup

Buy Tesamorelin Peptide Benefits: What Does the Research Say?

Before you buy Tesamorelin online, it helps to understand what current research suggests about its potential applications. Below, we break down the key study areas.

Buy Tesamorelin and Lipodystrophy

Lipodystrophy models refer to abnormal or pathological fat distribution and metabolism. The primary feature is irregular fat distribution — loss of fat (lipoatrophy) from specific areas alongside excess fat accumulation (lipohypertrophy) elsewhere. This pattern often associates with serious metabolic changes, including insulin resistance and elevated cholesterol and triglyceride levels. Test models exhibiting lipodystrophy typically report low GH and IGF-1 levels.

Two phase III studies followed 806 test subjects with immunodeficiencies and lipodystrophy over 26 weeks, plus a 26-week extension. Researchers divided subjects into a Tesamorelin group (543 subjects) and a placebo group (263 subjects). At week 26, the Tesamorelin group showed a significant decrease in visceral adipose tissue — at least 15.4% — along with significantly decreased triglyceride and cholesterol levels compared to placebo.

Buy Tesamorelin and Immunodeficient Fat Fractions

Researchers posit that serious immunodeficiencies may induce non-alcoholic fatty liver disease (NAFLD), which clinical reports link to nearly 40% of HIV-positive test models. In one study, 61 test subjects with HIV and a high hepatic fat fraction (HFF) received either Tesamorelin or a placebo for 12 months. After this period, 35% of Tesamorelin subjects showed an apparent HFF reduction of less than 5%, compared to only 4% of placebo subjects. Researchers reported no alteration in glucose levels.

Buy Tesamorelin and Cognition

A clinical study observed immunodeficient models with mild cognitive impairment to determine Tesamorelin’s potential effect on neurological functioning. 100 subjects over age 40 received Tesamorelin daily for 6 months, followed by 6 months without it, then a further 6-month reintroduction period. Researchers measured neurocognitive performance using the Global Deficit Score (GDS) at 6 and 12 months. This study remains underway, and final results have not yet been published.

Buy Tesamorelin and Insulin Sensitivity

This study aimed to determine whether Tesamorelin might alter insulin sensitivity. Researchers observed 53 test subjects with Type II diabetes across a 12-week randomized trial, divided into three groups receiving low-dose, high-dose, or placebo Tesamorelin. After 12 weeks, researchers found no significant reduction in fasting glucose, glycosylated hemoglobin, or diabetes control — results across all three groups appeared similar.

Buy Tesamorelin and Muscle Tissue

Researchers used computed tomography (CT) scans to evaluate Tesamorelin’s possible impact on muscle tissue structure. Findings tentatively suggested an association between Tesamorelin and improvements in muscle density and volume, with the most noticeable variations in the rectus abdominis, psoas major, and paraspinal muscles. These changes — including increased density and volume or decreased intramuscular fat — were statistically significant compared to placebo.

Tesamorelin and Visceral Fat Reduction

Visceral obesity involves excess fat accumulation around and within internal organs, often observed in lipodystrophy models. This condition links to several metabolic issues, including insulin resistance, atherosclerosis, elevated LDL cholesterol, and hyperuricemia. Research into Tesamorelin suggests it may lead to a reduction of up to 25% in visceral fat among lipodystrophy models.

Tesamorelin Price and Available Options

Sino Research Peptide Manufacturer offers competitive Tesamorelin price points across our research-grade inventory, without ever compromising on purity. Every batch undergoes strict quality testing to ensure consistency for laboratory use.

Best Time to Take Tesamorelin: A Research Protocol Consideration

Administration timing in Tesamorelin research protocols varies by study design and institutional guidelines. Since dosing schedules depend entirely on the specific research objective, we recommend consulting your institution’s approved protocols and ethical guidelines before beginning any study involving this peptide.

Where to Buy Tesamorelin Peptide

Best Place to Buy Tesamorelin Online

If you’ve been searching for the best place to buy Tesamorelin online, Sino Research Peptide Manufacturer offers a straightforward, reliable path to research-grade material. Every batch ships with purity verification, so you always know exactly what you’re working with.

Tesamorelin Peptide for Sale

We keep Tesamorelin peptide for sale in laboratory-ready formats designed for research consistency. Whether you’re placing your first order or restocking for an ongoing study, our team supports your research timeline with fast, dependable supply.

Tesamorelin Peptide Where to Buy

Not sure where to buy Tesamorelin peptide? Sino Research Peptide Manufacturer makes ordering simple through our streamlined online platform, with secure checkout and tracked delivery to laboratories and institutions.

Important Research Notice

Tesamorelin peptide is available for research and laboratory purposes only. It is not intended for human or veterinary use. Please review and adhere to our Terms and Conditions before placing an order.

References:

1. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tesamorelin. [Updated 2018 Oct 20]. https://www.ncbi.nlm.nih.gov/books/NBK548730/
2. Spooner, L. M., & Olin, J. L. (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. The Annals of pharmacotherapy, 46(2), 240–247. https://doi.org/10.1345/aph.1Q629
3. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011 Jan;96(1):150-8. doi: 10.1210/jc.2010-1587. Epub 2010 Oct 13. PMID: 20943777; PMCID: PMC3038486. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038486/
4. Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):49-58. doi: 10.1111/j.1742-7843.2007.00008.x. PMID: 17214611. https://pubmed.ncbi.nlm.nih.gov/17214611/
5. Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Aepfelbacher, J., Buckless, C., Tsao, A., Kellogg, A., Branch, K., Lee, H., Liu, C. Y., Corey, K. E., Chung, R. T., Torriani, M., Kleiner, D. E., Hadigan, C. M., & Grinspoon, S. K. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The lancet. HIV, 6(12), e821–e830. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981288/
6. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
7. Tesamorelin Effects on Liver Fat and Histology in HIV. https://clinicaltrials.gov/ct2/show/NCT02196831
8. Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons. https://clinicaltrials.gov/ct2/show/record/NCT02572323
9. Clemmons, D. R., Miller, S., & Mamputu, J. C. (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PloS one, 12(6), e0179538. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472315/
10. Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. doi: 10.14283/jfa.2018.45. PMID: 31237318; PMCID: PMC6766405. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766405/
11. Sivakumar T, Mechanic O, Fehmie DA, Paul B. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. HIV Med. 2011 Sep;12(8):453-62. doi: 10.1111/j.1468-1293.2010.00906.x. Epub 2011 Jan 25. PMID: 21265979.